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We are thankful for the response from
Camoinet al. (1) toourarticle (2) showing
the association of severe diabetic reti-
nopathy (SDR) with cardiovascular dis-
ease, including peripheral artery disease,
in long-standing type 1 diabetes. Impor-
tantly, the association was present even
in the absence of DKD, a well-established
risk factor for cardiovascular events and
premature mortality (3). Results from
the French cohort of patients with type 1
diabetes further strengthen the impor-
tance of SDR as a risk factor for lower-
extremity ischemia, foot ulcers, and
amputations. In their cohort (n 5 204)
they were able to show an association
between SDR and foot ulcers after ad-
justment for the presence of DKD and
other cardiovascular risk factors, even
with shorter diabetes duration (21 6 13
years) and shorter follow-up (7 years).
Moreover, they propose that the associ-
ation is mediated through peripheral neu-
ropathy, since it was more prevalent in their
patients with SDR. However, they do not
present data on the association between
peripheral neuropathy and cardiovascular
disease, myocardial infarction, and stroke.
Similarly, data from the Diabetes
Control and Complications Trial/
Epidemiology of Diabetes Interventions
and Complications (DCCT/EDIC) study
reported an independent association
between cardiac autonomic neuropathy
and cardiovascular events, also after
adjustment for albuminuria, but not spe-
ciﬁcally between peripheral neuropathy
and cardiovascular events (4). In addi-
tion, data from the Joslin Diabetes Cen-
ter’s cohort of patients with very long
type 1 diabetes duration also do not
point to the association of peripheral neu-
ropathy and cardiovascular events (5). In-
terestingly, however, recently published
data from the Canadian Study of Lon-
gevity in Type 1 Diabetes cohort (n5 69)
show that coronary artery calcium scores
were higher in patients with sensory
polyneuropathy and diabetic retinopa-
thy, but not with DKD or autonomic
neuropathy (6). However, since coronary
calciﬁcation scores cannot differentiate
between stable and vulnerable plaques,
they could not reliably predict incident
acute cardiovascular events.
Associations of SDR or peripheral neu-
ropathy with cardiovascular disease in
the absence of DKD are important, as
they suggest the need for continued
vigilance to reduce cardiovascular risk
even in the absence of DKD and in long-
standing diabetes (2). Since both mi-
crovascular and macrovascular disease
share similar risk factors in long-standing
diabetes (4), the independent associa-
tion of isolated sensory polyneuropathy
with cardiovascular disease would be
of no surprise, but it has not yet been
shown. Until more longitudinal and
mechanistic data become available, SDR
should be regarded as an independent
risk factor for critical limb ischemia and
foot ulcers, as well as for other types of
cardiovascular disease. Therefore, regular
diabetic foot screening tests in this pop-
ulation are of the utmost importance.
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